Reshma Ramachandran, MD, MPP, MHS, not only believes in equitable access to healthcare and medical products but is a formidable force in advocating for it.
Reshma Ramachandran, MD, MPP, MHS
Assistant Professor of Medicine (General Medicine)Cards
About
Reshma Ramachandran is a primary care physician trained in family medicine and health services researcher. Her research focuses on developing evidence-driven strategies to ensure equitable access to meaningfully effective and safe health innovations in the United States and abroad.
Research
Publications
2026
Pharmaceutical Manufacturer Kickback Resolutions and Associated Financial Penalties, 2000-2025
Liu T, Ross J, Morten C, Ramachandran R. Pharmaceutical Manufacturer Kickback Resolutions and Associated Financial Penalties, 2000-2025. JAMA Network Open 2026, 9: e261735. PMID: 41823969, PMCID: PMC12988444, DOI: 10.1001/jamanetworkopen.2026.1735.Peer-Reviewed Original ResearchFDA approval of benzgalantamine exposes flaws in the 505(b)(2) pathway for innovations on existing drugs
Reddy N, Steinman M, Ross J, Widera E, Zeldes N, Steinbrook R, Ramachandran R. FDA approval of benzgalantamine exposes flaws in the 505(b)(2) pathway for innovations on existing drugs. BMJ Evidence-Based Medicine 2026, bmjebm-2025-114142. PMID: 41771551, DOI: 10.1136/bmjebm-2025-114142.Peer-Reviewed Original ResearchPolitics, Science, and the Future of FDA Drug Regulation
Ramachandran R, Morten C. Politics, Science, and the Future of FDA Drug Regulation. JAMA: The Journal Of The American Medical Association 2026, 335: 585-587. PMID: 41525060, DOI: 10.1001/jama.2025.24868.Peer-Reviewed Original ResearchPremarket and postmarket real-world evidence studies supporting U.S. Food and Drug Administration regulatory decision-making, 2016-2024.
Li L, Ramachandran R, Ross J, Wallach J. Premarket and postmarket real-world evidence studies supporting U.S. Food and Drug Administration regulatory decision-making, 2016-2024. Clinical Trials 2026, 17407745251415190. PMID: 41641793, PMCID: PMC12900038, DOI: 10.1177/17407745251415190.Peer-Reviewed Original ResearchFood and Drug AdministrationU.S. Food and Drug AdministrationReal-world dataReal-world evidence studiesElectronic health recordsDrug AdministrationEvidence studiesElectronic healthNovel therapeuticsHealth recordsData sourcesStudy designNon-interventionalDeterminants of effectivenessReview documentsAdministrative claims dataMedical recordsPatient RegistryPostmarket Drug Safety−Related Actions Before and After the US Food and Drug Administration Amendments Act
Doernberg H, Wallach J, Jeffery M, Mooghali M, Ramachandran R, Ross J. Postmarket Drug Safety−Related Actions Before and After the US Food and Drug Administration Amendments Act. JAMA Internal Medicine 2026, 186: 233-242. PMID: 41359349, PMCID: PMC12687201, DOI: 10.1001/jamainternmed.2025.6566.Peer-Reviewed Original ResearchPolypharmacy Among US Older Adults with Limited English Proficiency: 2013–2018
Wan Y, Ramachandran R, Muir K, Ross J. Polypharmacy Among US Older Adults with Limited English Proficiency: 2013–2018. Journal Of General Internal Medicine 2026, 1-8. PMID: 41593228, DOI: 10.1007/s11606-026-10228-6.Peer-Reviewed Original ResearchMedical Expenditure Panel SurveyCommunity-dwelling older adultsOlder adultsHealth characteristicsMedical Expenditure Panel Survey respondentsSample of community-dwelling older adultsUS older adultsCommunity-dwelling adultsAssociated with frailtyLimited English proficiencyMultivariate logistic regression modelCross-sectional analysisFederal poverty lineLogistic regression modelsEnglish proficiencyMain MeasuresWeInappropriate medicationsChronic conditionsMedication adherencePrescription medicationsUS household surveyPoverty lineHousehold surveyUnadjusted analysisPrescribing practicesPostmarket Safety Actions for Novel Oncology Drugs Granted FDA’s Accelerated Approval
Mooghali M, Wallach J, Mitchell A, Ross J, Ramachandran R. Postmarket Safety Actions for Novel Oncology Drugs Granted FDA’s Accelerated Approval. JAMA Network Open 2026, 9: e2553764. PMID: 41528751, PMCID: PMC12801081, DOI: 10.1001/jamanetworkopen.2025.53764.Peer-Reviewed Original ResearchVenture Capital Investments by Academic Medical Centers in Health Care Companies
Dhawan R, Shay D, Leland A, Ramachandran R, Ross J, Wallach J. Venture Capital Investments by Academic Medical Centers in Health Care Companies. JAMA Internal Medicine 2026, 186: 131-134. PMID: 41182783, PMCID: PMC12584060, DOI: 10.1001/jamainternmed.2025.5480.Peer-Reviewed Original Research
2025
Changes in pharmaceutical industry payments to physicians after New Jersey's 2018 restriction
Patel N, Ramachandran R, Ross J. Changes in pharmaceutical industry payments to physicians after New Jersey's 2018 restriction. Health Affairs Scholar 2025, 4: qxaf254. PMID: 41536639, PMCID: PMC12798812, DOI: 10.1093/haschl/qxaf254.Peer-Reviewed Original ResearchLevel of Evidence and Strength of Recommendations in US Medical Society Clinical Practice Guidelines, 2019–2023: A Cross-Sectional Analysis
Qureshi O, Ross J, Ramachandran R, Habib A. Level of Evidence and Strength of Recommendations in US Medical Society Clinical Practice Guidelines, 2019–2023: A Cross-Sectional Analysis. Journal Of General Internal Medicine 2025, 1-11. PMID: 41428154, DOI: 10.1007/s11606-025-10088-6.Peer-Reviewed Original ResearchClinical practice guidelinesEvidence-based patient careModified gradingModified Grading of RecommendationsPractice guidelinesGuideline writing committeesLevel of evidenceGrading of RecommendationsStrength of recommendationsPractice guideline documentsClinical practice guideline documentCross-sectional analysisGuideline recommendationsCPG recommendationsSpecialty typeStrong recommendationPatient careModerate evidenceWriting committeeRating concordanceCohen's kappaGuideline documentsMedical societiesConcordanceLOE
Academic Achievements & Community Involvement
Clinical Care
Overview
Reshma Ramachandran, MD, is a physician specializing in internal medicine. She focuses on providing comprehensive care to adults, managing a diverse range of conditions, and promoting overall health and well-being through preventive measures and wellness strategies.
As an assistant professor of medicine at Yale School of Medicine, Dr. Ramachandran’s research is aimed at enhancing patient access to safe and effective health technologies. Her work concentrates on aligning healthcare incentives to prioritize equitable access, benefiting patients by improving healthcare policies related to medical product evaluation, approval, and coverage.
Dr. Ramachandran received her medical degree from the Alpert Medical School at Brown University and completed her family medicine residency at Kaiser Permanente Los Angeles Medical Center. She further honed her skills through a health services research and policy fellowship at the National Clinician Scholars Program at Yale.
News
News
- January 12, 2026Source: Regulatory Affairs Professionals Society
Experts raise concerns over lower evidentiary standard for FDA's leucovorin approval
- September 05, 2025Source: Medical Marketing & Media Online
Experts throw cold water on the idea that DTC platforms will meaningfully lower drug prices
- July 08, 2025Source: The New York Times Magazine
Inside the Collapse of the F.D.A.
- May 13, 2025Source: Lown Institute
Reshma Ramachandran, Winner of the 2025 Bernard Lown Award
Get In Touch
Contacts
Locations
E.S. Harkness Memorial Hall, Building A
Academic Office
367 Cedar Street, Rm 406A
New Haven, CT 06510
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.